Table 1.
Baseline Patient Characteristics: Full Analysis Set
| Placebo N = 194 | Fosnetupitant at a Dose of 81 mg N = 195 | Fosnetupitant at a Dose of 235 mg N = 195 | |
|---|---|---|---|
| Sex, no. (%) | |||
| Male | 147 (75.8) | 146 (74.9) | 148 (75.9) |
| Female | 47 (24.2) | 49 (25.1) | 47 (24.1) |
| Age, y | |||
| Median | 67.0 | 66.0 | 67.0 |
| Range | 36‐79 | 41‐76 | 37‐78 |
| Age category, no. (%) | |||
| <55 y | 24 (12.4) | 25 (12.8) | 22 (11.3) |
| ≥55 y | 170 (87.6) | 170 (87.2) | 173 (88.7) |
| Drinking history, no. (%) | |||
| No | 71 (36.6) | 70 (35.9) | 67 (34.4) |
| Rarely (once per mo) | 18 (9.3) | 22 (11.3) | 23 (11.8) |
| Occasionally | 18 (9.3) | 21 (10.8) | 24 (12.3) |
| Regularly | 87 (44.8) | 82 (42.1) | 81 (41.5) |
| Smoking history, no. (%) | |||
| Nonsmoker | 41 (21.1) | 33 (16.9) | 40 (20.5) |
| Stopped smoking prior to 180 d before registration | 82 (42.3) | 88 (45.1) | 87 (44.6) |
| Stopped smoking within 180 d before registration | 51 (26.3) | 63 (32.3) | 52 (26.7) |
| Smoker | 20 (10.3) | 11 (5.6) | 16 (8.2) |
| ECOG performance status, no. (%) | |||
| 0 | 124 (63.9) | 125 (64.1) | 113 (57.9) |
| 1 | 70 (36.1) | 70 (35.9) | 82 (42.1) |
| Cancer type, no. (%) | |||
| Lung | 184 (94.8) | 184 (94.4) | 187 (95.9) |
| Other | 10 (5.2) | 11 (5.6) | 8 (4.1) |
| Prior systemic drug therapies, no. (%) | |||
| No | 175 (90.2) | 175 (89.7) | 167 (85.6) |
| Yes | 19 (9.8) | 20 (10.3) | 28 (14.4) |
| Chemotherapy regimen, no. (%) | |||
| Cisplatin plus vinorelbine tartrate | 69 (35.6) | 66 (33.8) | 56 (28.7) |
| Cisplatin plus pemetrexed | 56 (28.9) | 57 (29.2) | 63 (32.3) |
| Cisplatin plus pemetrexed plus bevacizumab | 29 (14.9) | 32 (16.4) | 29 (14.9) |
| Cisplatin plus etoposide | 24 (12.4) | 21 (10.8) | 24 (12.3) |
| Cisplatin plus other cancer treatment | 16 (8.2) | 19 (9.7) | 23 (11.8) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.